Elm Street Ventures

Halda Therapeutics is a research-stage drug discovery company dedicated to developing next-generation precision medicine. The company employs a unique therapeutic modality that serves as a platform for addressing various disease states. By focusing on the discovery of novel therapies that modify disease-causing pathways, Halda Therapeutics aims to enable healthcare providers to offer more targeted treatments for their patients. Through its innovative approach, the company seeks to advance the field of precision medicine and improve patient outcomes.

EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

CellFE Inc. is a biotechnology company based in San Carlos, California, established in 2017. It specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. This innovative platform enhances the manufacturing and development of cell therapies by utilizing rapid cell compression techniques that facilitate the uptake of therapeutic molecules from surrounding fluids. By enabling the transport of hard-to-deliver molecules, CellFE aims to improve the effectiveness of treatments for various disorders, supporting medical researchers in their efforts to advance patient care and outcomes.

Founded in 2009 by Yale scientists and a chemical industry veteran, P2 Science is a venture-backed company specializing in renewable specialty chemicals. It converts renewable feedstocks like vegetable oils into high-value products such as flavor, fragrance, and cosmetics ingredients, serving diverse markets including food, personal care, and industrial cleaning.

Allyx Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2018 and based in Durham, Connecticut. The company specializes in developing disease-modifying treatments for Alzheimer's Disease, with a focus on reversing neurodegeneration. Its lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative approach aims to provide clinicians with a therapeutic option capable of preserving cognition in patients while addressing the underlying disease mechanisms.

Cybrexa Therapeutics is a biotechnology company focused on developing an innovative class of small molecule DNA repair inhibitors aimed at improving cancer treatment. Founded in 2016 and based in New Haven, Connecticut, Cybrexa utilizes a proprietary peptide-based technology that specifically targets the tumor microenvironment. This approach allows for enhanced drug delivery and increased therapeutic efficacy, particularly when combined with existing chemotherapies and radiotherapies. By enabling the safe administration of higher drug doses, Cybrexa's therapeutics aim to expand the efficacy of current anticancer agents and address significant unmet medical needs in oncology. The company's novel platform has the potential to redefine drug delivery paradigms and enhance patient outcomes in cancer care.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

Founded in 2009 by Yale scientists and a chemical industry veteran, P2 Science is a venture-backed company specializing in renewable specialty chemicals. It converts renewable feedstocks like vegetable oils into high-value products such as flavor, fragrance, and cosmetics ingredients, serving diverse markets including food, personal care, and industrial cleaning.

CellFE Inc. is a biotechnology company based in San Carlos, California, established in 2017. It specializes in the development of a microfluidics-based device designed to deliver gene-editing molecules into human cells. This innovative platform enhances the manufacturing and development of cell therapies by utilizing rapid cell compression techniques that facilitate the uptake of therapeutic molecules from surrounding fluids. By enabling the transport of hard-to-deliver molecules, CellFE aims to improve the effectiveness of treatments for various disorders, supporting medical researchers in their efforts to advance patient care and outcomes.

EvolveImmune Therapeutics is a biotechnology company focused on developing innovative immunotherapies aimed at addressing unmet needs in oncology and autoimmune diseases. The company has created an advanced immunobiological platform that combines sustained immune activation with targeted tumor cell therapy in a single agent. Through its unique approach, EvolveImmune's biotherapeutics utilize engineered extracellular vesicles to directly target tumor cells and enhance cytokine secretion at the tumor site, thereby improving tumor destruction while minimizing toxicity. The company is actively building a pipeline of novel therapeutic candidates that leverage its proprietary in vivo target discovery platform, enabling more effective treatment options for patients suffering from various diseases.

Zid is a cloud-based multi-channel commerce platform tailored for small and medium-sized businesses in Saudi Arabia. Founded in 2017 and headquartered in Riyadh, Zid enables merchants to create their own branded eStores while integrating with various supply chain players. The platform offers a comprehensive suite of tools that allow users to manage products and inventory, process orders and payments, ship products, and build customer relationships. It also provides analytics and reporting features, facilitating data-driven decision-making, and offers access to financing options. Zid's mission is to simplify the entry of retailers into electronic commerce, making it accessible and professional for businesses in the region.

Artizan Biosciences, Inc. is a biotechnology company focused on developing small molecule drugs for human use, particularly targeting diseases linked to intestinal inflammation. Founded in 2016 and headquartered in New Haven, Connecticut, the company employs its proprietary IgA-SEQ technology platform to identify and characterize disease-driving bacteria within the intestinal microbiota. This innovative approach aims to create precision therapeutics that address the root causes of various serious conditions, including digestive disorders, obesity, autoimmune diseases, and a range of other health issues affecting the skin, lungs, and central nervous system. By focusing on unmet medical needs, Artizan Biosciences seeks to provide novel treatment options for patients.

Halda Therapeutics is a research-stage drug discovery company dedicated to developing next-generation precision medicine. The company employs a unique therapeutic modality that serves as a platform for addressing various disease states. By focusing on the discovery of novel therapies that modify disease-causing pathways, Halda Therapeutics aims to enable healthcare providers to offer more targeted treatments for their patients. Through its innovative approach, the company seeks to advance the field of precision medicine and improve patient outcomes.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

Saphlux, Inc. is a company based in New Haven, Connecticut, that specializes in the development, production, and commercialization of advanced semi-polar gallium nitride (GaN) materials. Founded in 2014, Saphlux addresses critical challenges in LED and laser technology, specifically targeting droop and green gap issues. The company offers semi-polar GaN templates in various sizes and is known for its innovative quantum dot (QD) technology integrated into micro-LED solutions. Saphlux designs and manufactures micro-LED chips and micro-display modules, including the NPQD R1 chip for public information displays and the NPQD T1 micro-display for augmented reality glasses. With a focus on enhancing output power and performance while reducing costs, Saphlux operates on a global scale, serving markets in the United States, China, and Japan.

Founded in 2009 by Yale scientists and a chemical industry veteran, P2 Science is a venture-backed company specializing in renewable specialty chemicals. It converts renewable feedstocks like vegetable oils into high-value products such as flavor, fragrance, and cosmetics ingredients, serving diverse markets including food, personal care, and industrial cleaning.

SeeClickFix is a platform that enables residents to report non-emergency issues and helps governments track, manage, and respond to requests, promoting transparency and collaboration in local governance. The company offers tools for request management, work management, citizen engagement, and data analytics to improve data collection, service delivery, and reporting to stakeholders. Its backend centralizes every reported issue, while its mobile app brings city information into residents’ hands and its dashboards support data-driven decisions. SeeClickFix serves municipalities and educational institutions by facilitating issue reporting, service coordination, and public accountability, enabling officials to evaluate performance, plan improvements, and communicate outcomes to communities.

Device42, Inc. is a software company that specializes in providing solutions for system, network, and data center engineers, as well as IT managers. Founded in 2010 and headquartered in West Haven, Connecticut, with an additional office in Boston, Massachusetts, Device42 offers a comprehensive suite of tools designed for IT inventory management, patch panel cable management, data center power management, and IP address tracking. Its platform includes essential features such as Configuration Management Database (CMDB), Application Dependency Mapping (ADM), and a DCIM Software Marketplace, all aimed at helping organizations maintain accurate inventories of both IP-based and non-IP assets. The software facilitates various IT operations, compliance auditing, migration, and modernization processes, making it easier for clients to manage hybrid IT environments and execute successful cloud migrations while ensuring compliance with internal and external regulations.

Device42, Inc. is a software company that specializes in providing solutions for system, network, and data center engineers, as well as IT managers. Founded in 2010 and headquartered in West Haven, Connecticut, with an additional office in Boston, Massachusetts, Device42 offers a comprehensive suite of tools designed for IT inventory management, patch panel cable management, data center power management, and IP address tracking. Its platform includes essential features such as Configuration Management Database (CMDB), Application Dependency Mapping (ADM), and a DCIM Software Marketplace, all aimed at helping organizations maintain accurate inventories of both IP-based and non-IP assets. The software facilitates various IT operations, compliance auditing, migration, and modernization processes, making it easier for clients to manage hybrid IT environments and execute successful cloud migrations while ensuring compliance with internal and external regulations.

Founded in 2009 by Yale scientists and a chemical industry veteran, P2 Science is a venture-backed company specializing in renewable specialty chemicals. It converts renewable feedstocks like vegetable oils into high-value products such as flavor, fragrance, and cosmetics ingredients, serving diverse markets including food, personal care, and industrial cleaning.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Founded in 2009 by Yale scientists and a chemical industry veteran, P2 Science is a venture-backed company specializing in renewable specialty chemicals. It converts renewable feedstocks like vegetable oils into high-value products such as flavor, fragrance, and cosmetics ingredients, serving diverse markets including food, personal care, and industrial cleaning.

Desmos, Inc. is a San Francisco-based company that specializes in developing a web-based graphing calculator aimed at enhancing mathematical education for students and teachers both in the United States and internationally. Founded in 2007 and originally known as Tutor Trove, LLC, Desmos offers an interactive platform that allows users to graph functions, plot data tables, evaluate equations, and explore transformations effortlessly. Its platform is designed to be platform-agnostic, enabling seamless access on various devices without the need for downloads. By providing an engaging and user-friendly math engine, Desmos aims to make mathematics more accessible and enjoyable, thereby bridging the gap between classroom learning and home study.

Accelerated Orthopedic Technologies, Inc. is a Guilford, Connecticut-based company that specializes in developing proprietary instruments for the treatment of articular cartilage defects. The company offers custom sizes, shapes, and matching topography for cartilage grafts, which are essential for addressing joint-related issues. Founded in 2009 and initially known as Advanced Orthopedic Technologies, the company rebranded to its current name in February 2010. Through its innovative approach, Accelerated Orthopedic Technologies aims to improve surgical outcomes and enhance patient care in orthopedic procedures.

Metagenomix is an early-stage biotechnology company developing novel methods of screening microbes for pharmacologically active compounds. Among the indications under investigation are cancer, inflammation and infectious diseases including fungal infections and malaria. The technology also has applications in agriculture.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company specializes in the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs), which play a crucial role in various cancers and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as KIT-ADC, an antibody-drug conjugate for oncology applications. The company is also engaged in various research programs focused on RTK targets, building on foundational discoveries made in collaboration with leading academic laboratories. As of late 2016, Kolltan Pharmaceuticals operates as a subsidiary of Celldex Therapeutics, Inc.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

ShareGrove is a provider of an online conversations platform that facilitates rich and dynamic private discussions among users. By allowing individuals to select friends from Facebook and other social networks, ShareGrove enables real-time and asynchronous engagement through a unified web interface. The platform enhances user interactions with integrated web search capabilities from major sources, alongside inline media presentations, thereby enriching the conversational experience. Additionally, ShareGrove generates revenue through affiliate programs linked to its media-rich content.

Retail Optimization Inc. specializes in providing predictive macro optimization analytics designed to enhance profitability in the retail sector. The company offers solutions for space management, store remodeling, and assortment planning, enabling retailers and suppliers to optimize product selection, category space, and inventory investment. By integrating consumer information, supply chain dynamics, market data, and store layouts, Retail Optimization Inc. helps clients determine the ideal category, aisle, department, and store size. This comprehensive approach not only improves operational efficiency but also enhances the overall shopping experience for consumers.

Affomix is a biotechnology firm specializing in the development of antibody-based products, leveraging proprietary technology for the rapid and automated selection of human monoclonal antibodies (mAbs). The company focuses on commercializing its mAbs, mAb microarrays, and mAb libraries for a variety of applications, including research, drug discovery, diagnostics, and therapeutics. Affomix's innovative approach enables high-throughput production and screening of antibodies against a wide range of human proteins, including those that are post-translationally modified. This technology is particularly aimed at facilitating the sensitive and accurate measurement of numerous proteins in biological samples, thereby advancing the field of protein analysis and improving the efficacy of therapeutic solutions.

BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.